Abstract
Background
Transcatheter Tricuspid Valve Replacement (TTVR) has emerged as a treatment option for patients with severe tricuspid regurgitation (TR) who are at high surgical risk and unsuitable for tricuspid transcatheter edge-to-edge repair (T-TEER).
Objectives
This study aims to compare procedural, clinical and echocardiographic outcomes of two different TTVR devices: the Cardiovalve (Venus MedTech) and the EVOQUE (Edwards Lifesciences) prosthesis.
Methods
We performed a retrospective, single-center cohort analysis including all consecutive patients who were treated with TTVR. Primary endpoints included TR reduction, NYHA class and safety events according to TVARC criteria.
Results
Overall, 25 consecutive patients were included in the analysis. The Cardiovalve prosthesis was implanted in 12 patients and the EVOQUE prosthesis in 13 patients. Intraprocedural success was 100%. There was a significant reduction in TR grade (4.20 vs. 0.48;
p
p
= 0.004) for the overall cohort at 30-day follow-up, but no differences between the two devices (TR grade 0.50 vs. 0.46;
p
= 0.408 and NYHA class 1.75 vs. 2.00;
p
= 0.813; Cardiovalve and EVOQUE respectively). Mortality rate at 30 days was 0% in both groups. One patient in each group (8.0%) required new pacemaker implantation.
Conclusion
TTVR with both, the Cardiovalve and EVOQUE prothesis is an effective treatment option, leading to profound TR reduction and meaningful clinical improvement at 30-day follow-up. Patient selection and long term follow up need to be the focus of future studies.